Outlook Therapeutics Inc Stock Performance
| OTLK Stock | USD 2.01 0.31 18.24% |
The company holds a Beta of -0.62, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning OUTLOOK THERAPEUTICS are expected to decrease at a much lower rate. During the bear market, OUTLOOK THERAPEUTICS is likely to outperform the market. At this point, OUTLOOK THERAPEUTICS INC has a negative expected return of -0.75%. Please make sure to check OUTLOOK THERAPEUTICS's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if OUTLOOK THERAPEUTICS INC performance from the past will be repeated at some future point.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OUTLOOK THERAPEUTICS INC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's essential indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 18.24 | Five Day Return 38.62 | Year To Date Return (74.43) | Ten Year Return (99.71) | All Time Return (99.71) |
Last Split Factor 1:20 | Dividend Date 2019-03-18 | Last Split Date 2024-03-14 |
1 | Acquisition by Thurman Randy H of 89549 shares of OUTLOOK THERAPEUTICS at 5.22 subject to Rule 16b-3 | 10/09/2024 |
2 | Acquisition by Auffarth Gerd of 56636 shares of OUTLOOK THERAPEUTICS at 5.22 subject to Rule 16b-3 | 10/11/2024 |
3 | Great Point Partners LLC Bolsters Position in Outlook Therapeutics Inc | 11/15/2024 |
4 | Owning 30 percent shares,institutional owners seem interested in Outlook Therapeutics, Inc. , | 11/26/2024 |
5 | Outlook Therapeutics Announces Preliminary Topline Results of N | 11/27/2024 |
6 | Investors Purchase Large Volume of Call Options on Outlook Therapeutics | 11/29/2024 |
7 | UK productivity crisis worse than feared amid migration surge | 12/03/2024 |
8 | Muhammad most popular boys baby name in England and Wales for first time | 12/06/2024 |
9 | UK economy shrinks again in October in blow to Starmers budget - live updates | 12/13/2024 |
10 | Thinking to buy more of OUTLOOK THERAPEUTICS | 12/19/2024 |
11 | Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -4.06, Missing Revenue Estimate of 0. ... | 12/27/2024 |
| Begin Period Cash Flow | 23.4 T |
OUTLOOK |
OUTLOOK THERAPEUTICS Relative Risk vs. Return Landscape
If you would invest 534.00 in OUTLOOK THERAPEUTICS INC on September 30, 2024 and sell it today you would lose (333.00) from holding OUTLOOK THERAPEUTICS INC or give up 62.36% of portfolio value over 90 days. OUTLOOK THERAPEUTICS INC is currently does not generate positive expected returns and assumes 9.9347% risk (volatility on return distribution) over the 90 days horizon. In different words, 88% of stocks are less volatile than OUTLOOK, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OUTLOOK THERAPEUTICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OUTLOOK THERAPEUTICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OUTLOOK THERAPEUTICS INC, and traders can use it to determine the average amount a OUTLOOK THERAPEUTICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0751
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OTLK |
Estimated Market Risk
| 9.93 actual daily | 88 88% of assets are less volatile |
Expected Return
| -0.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OUTLOOK THERAPEUTICS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OUTLOOK THERAPEUTICS by adding OUTLOOK THERAPEUTICS to a well-diversified portfolio.
OUTLOOK THERAPEUTICS Fundamentals Growth
OUTLOOK Stock prices reflect investors' perceptions of the future prospects and financial health of OUTLOOK THERAPEUTICS, and OUTLOOK THERAPEUTICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OUTLOOK Stock performance.
| Return On Equity | -0.0365 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 48.25 M | ||||
| Shares Outstanding | 23.66 M | ||||
| Price To Earning | (1.24) X | ||||
| Price To Book | 10.19 X | ||||
| Price To Sales | 13.27 X | ||||
| Revenue | 5.85 M | ||||
| Gross Profit | (42.33 M) | ||||
| EBITDA | (71.7 T) | ||||
| Net Income | (75.37 T) | ||||
| Cash And Equivalents | 26.02 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 297.83 B | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | (3.58) X | ||||
| Cash Flow From Operations | (68.79 T) | ||||
| Earnings Per Share | (4.06) X | ||||
| Market Capitalization | 47.55 M | ||||
| Total Asset | 28.82 T | ||||
| Retained Earnings | (543.28 T) | ||||
| Working Capital | (15.75 M) | ||||
| Current Asset | 4.12 M | ||||
| Current Liabilities | 28.27 M | ||||
About OUTLOOK THERAPEUTICS Performance
By examining OUTLOOK THERAPEUTICS's fundamental ratios, stakeholders can obtain critical insights into OUTLOOK THERAPEUTICS's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that OUTLOOK THERAPEUTICS is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.17) | (0.18) | |
| Return On Tangible Assets | (2.61) | (2.75) | |
| Return On Capital Employed | 5.22 | 5.48 | |
| Return On Assets | (2.61) | (2.75) | |
| Return On Equity | 1.03 | 1.08 |
Things to note about OUTLOOK THERAPEUTICS INC performance evaluation
Checking the ongoing alerts about OUTLOOK THERAPEUTICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OUTLOOK THERAPEUTICS INC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OUTLOOK THERAPEUTICS generated a negative expected return over the last 90 days | |
| OUTLOOK THERAPEUTICS has high historical volatility and very poor performance | |
| OUTLOOK THERAPEUTICS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.85 M. Net Loss for the year was (75.37 T) with loss before overhead, payroll, taxes, and interest of (42.33 M). | |
| OUTLOOK THERAPEUTICS INC currently holds about 26.02 M in cash with (68.79 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| OUTLOOK THERAPEUTICS has a very weak financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -4.06, Missing Revenue Estimate of 0. ... |
- Analyzing OUTLOOK THERAPEUTICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OUTLOOK THERAPEUTICS's stock is overvalued or undervalued compared to its peers.
- Examining OUTLOOK THERAPEUTICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OUTLOOK THERAPEUTICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OUTLOOK THERAPEUTICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OUTLOOK THERAPEUTICS's stock. These opinions can provide insight into OUTLOOK THERAPEUTICS's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.